SCHEMBL2272508

SCHEMBL2272508

O=C(O)c1ccc(-c2ccccc2)cc1NC(=O)c1ccccc1-c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACLY P53396 7/20 0.63
HTT P42858 1/20 0.58
CHRNB2 P17787 2/20 0.58
CHRNB4 P30926 2/20 0.58
CHRNA3 P32297 2/20 0.58
CHRNA4 P43681 2/20 0.58
DHODH Q02127 1/20 0.57
MAPT P10636 1/20 0.57
ALDH1A1 P00352 2/20 0.54
HDAC1 Q13547 1/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
GFER P55789 1/20 0.53
SUCNR1 Q9BXA5 1/20 0.53
FABP3 P05413 1/20 0.53
FABP4 P15090 1/20 0.53
FABP5 Q01469 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2272453 0.85 ACLY (0.63) ACLYHTTDHODHALDH1A1HDAC1
SCHEMBL14429560 0.85 HTT (0.55) ACLYHTTCHRNB2CHRNB4CHRNA3
SCHEMBL2268189 0.84 ACLY (0.61) ACLYDHODHMAPTALDH1A1HDAC1
SCHEMBL5145099 0.84 ACLY (0.61) ACLYHTTDHODHHDAC1KMT2A
SCHEMBL2269604 0.84 ACLY (0.69) ACLYDHODHSUCNR1
SCHEMBL28925309 0.84 ACLY (0.64) ACLYDHODHHDAC1KMT2AMEN1
SCHEMBL1320352 0.84 ACMSD (0.68) ACLYDHODHHDAC1KMT2AMEN1
SCHEMBL2270222 0.83 DHODH (0.77) ACLYDHODHMAPTHDAC1KMT2A
SCHEMBL2275453 0.83 ACLY (0.76) ACLYDHODHMAPTHDAC1KMT2A
SCHEMBL2272800 0.82 HTT (0.52) HTTCHRNB2CHRNB4CHRNA3CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 ACLY 653/4885HTT 3716/4885CHRNB2 4838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.